首頁 > 市場調查報告書 > 食物/飲料

保健食品

市場調查報告書

商品編碼

1588572

全球食品藥品市場 - 2024-2031

Global Food as a Medicine Market - 2024-2031

出版日期: 2024年11月08日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

2023 年，全球食品藥品市場規模達到 47.1 億美元，預計到 2031 年將達到 115.1 億美元，2024-2031 年預測期間複合年成長率為 12.2%。

食物作為藥物是指在個人的健康計畫中優先考慮食物和飲食，以預防、減少或預防疾病症狀。「食物作為藥物」的健康管理方法挑戰了傳統醫學的基礎，傳統醫學主要依賴醫學技術的發展來使用藥物來治療健康和疾病。使用「食物作為藥物」可以透過改善實驗室工作、減少藥物和減少住院來降低疾病的嚴重程度，從而降低醫療費用。

許多受過教育和知識淵博的消費者更喜歡將食品作為一種藥物方法，而不是包括藥物和其他治療方法的藥物治療。例如，根據食品安全網路服務 (FSNS) 2023 年 5 月的一項研究，55% 的顧客願意支付溢價購買可以作為藥物、改善他們的健康和福祉的食品。

市場動態：

驅動程式和限制

慢性病盛行率上升

慢性病盛行率的增加極大地推動了食品藥品市場的成長，預計將在整個市場預測期內推動成長。隨著人們的健康意識越來越強，他們正在積極尋找預防疾病、增強免疫力、控制持續疾病以及透過食物治療來改善整體健康的方法。因此，食品越來越被視為實現這些健康目標的關鍵組成部分。

各種飲食策略，例如抗發炎食品、心血管替代品、抗衰老營養和排毒飲食，作為補充療法和現代醫療程序的重要組成部分越來越受歡迎。這種日益增強的意識正在使人們轉向以食物為中心的解決方案，隨著人們尋求自然、永續和有效的方法來管理和避免慢性病，預計這種意識將繼續下去。傳統的治療食品因其性質且無副作用而受到越來越多的需求。

例如，根據美國國立衛生研究院2024年的數據，到2030年，糖尿病盛行率預計將達到6.43億，這主要是由於發展中國家的糖尿病盛行率增加了150%。印度、中國、美國、印尼、日本、巴基斯坦、俄羅斯、巴西、義大利和孟加拉是糖尿病發生率最高的國家。糖尿病已被確定為全球嚴重的健康問題。低收入和中等收入國家的糖尿病病例成長速度遠快於高收入國家。

隨著癌症盛行率的不斷增加，人們越來越關注食品作為一種疾病預防方法，以降低健康風險，並將食品作為藥物。食物和癌症預防之間的關係變得越來越簡單，一些食物被認為具有潛在的抗癌作用。隨著世界各地癌症數量的增加，人們正在轉向可以幫助最大限度地減少疾病惡化機會的食物。由於心血管疾病是全球死亡的首要原因之一，透過食物支持心血管已成為食藥市場的重要組成部分。

人們對食物作為藥物的認知有限

對食品作為藥物方法的認知有限預計將阻礙食品作為藥物市場的成長。很大一部分人沒有意識到永續生產的食品對健康和環境的好處，這些食品可以預防和治療多種疾病。由於缺乏意識，生產商無法吸引那些可能對更健康、有機或環保產品感興趣的個人。在沒有充分了解其好處的情況下，客戶會選擇他們認為比食品更熟悉且更實惠的傳統食品作為藥物。

Food as a medicine refers to prioritizing food and diet in an individual's health plan to prevent, reduce, or prevent disease symptoms. The "food as a medicine" approach to health management challenges the foundation of conventional medicine, which depends primarily on technological medical developments to treat health and disease using pharmaceutical medications. Using "food as a medicine" may lower healthcare expenses by potentially reducing illness severity through improved labwork, fewer drugs, and fewer hospitalizations.

A large number of educated and knowledged consumers prefer food as a medicine approach over medications which includes drugs and other treatments. For instance, according to a study by the Food Safety Net Services (FSNS) in May 2023, 55% of customers are willing to pay a premium for food that can act as medicine, improving their health and well-being.

Market Dynamics: Drivers & Restraints

Rising prevalence of chronic diseases

The increasing prevalence of chronic diseases is significantly driving the growth of the food as a medicine market and is expected to drive throughout the market forecast period. As people are becoming more health conscious, they are actively looking for ways to prevent illnesses, increase immunity, manage ongoing illness, and improve their general well-being by adopting food as a medicine approach. As a result, food is increasingly regarded as a critical component in accomplishing these health goals.

Various dietary strategies, such as anti-inflammatory foods, cardiovascular alternatives, anti-aging nutrition, and detoxifying diets are gaining popularity as supplementary therapies and as essential components of modern healthcare procedures. This increasing awareness is shifting individuals toward food-centric solutions and is expected to continue as people seek natural, sustainable, and effective ways to manage and avoid chronic conditions. Traditional healing foods are gaining demand due to their nature and with no side effects.

For instance, according to the National Institute of Health in 2024, the prevalence of diabetes is expected to reach 643 million by 2030, which is mainly due to a 150% increase in developing nations. India, China, the United States, Indonesia, Japan, Pakistan, Russia, Brazil, Italy, and Bangladesh are the countries with the highest diabetes rates. Diabetes has been identified as a serious worldwide health concern. Diabetes cases are growing at a far faster rate in low- and middle-income countries than in high-income countries.

With the increasing prevalence of cancer, there is an increasing focus on food as a disease prevention approach to reduce health risks and use food as a medicine. The relationship between food and cancer prevention is becoming simpler, with several foods being identified as having potential anti-cancer effects. As the number of cancers increases around the world, people are turning to food that can help minimize their chance of worsening the disease. With cardiovascular disease as one of the top causes of mortality worldwide, cardiovascular support through food has become an important component of the food as medicine market.

Limited awareness among individuals about food as a medicine

Limited awareness of food as a medicine approach is expected to hinder food as a medicine market growth. A large proportion of people are unaware of the health and environmental benefits of sustainably produced foods which prevent and cure a large number of illnesses. Because of this lack of awareness, producers fail to attract individuals who may otherwise be interested in healthier, organic, or environmentally friendly products. Without an adequate understanding of the benefits, customers choose conventional food products that they believe to be more familiar and affordable over food as a medicine approach.

Segment Analysis

The global food as a medicine market is segmented based on product type, form, application, distribution channel and region.

Medical Foods segment is expected to dominate the food as a medicine market share

The medical foods segment holds a major portion of the food as a medicine market share and is expected to continue to hold a significant portion of the food as a medicine market share during the forecast period. Medical foods differ from the broader category of foods for special dietary use in that they are intended to meet the unique nutritional requirements of a disease or condition, must be used under medical supervision, and are intended for the specific dietary management of a disease or condition.

The segment is expected to dominate the food as a medicine market share due to the increasing awareness among individuals about nutritional therapies rather than completely depending on drugs to cure the disease. A wide range of medical foods with different compositions and various applications are being introduced by the food as a medicine market players which are contributing to the segment expansion.

A large number of key players are adopting strategies to increase production capacity and expand their businesses which is expected to drive the segment's expansion. With these strategies, companies are expanding their portfolios and penetrating other regions, which is driving the segment's growth and is expected to hold the major share in the food as medicine market.

For instance, in September 2024, Dutch Medical Food B.V. made its official entry into the Indian market via a strategic relationship with Pristine Pearl Pharma Pvt. Ltd. This collaboration represents the introduction of an innovative line of products to treat disease-related malnutrition in both adult and pediatric populations. The latest offerings are primarily targeted at illnesses such as cancer, pediatric malnutrition, COPD, and drug-resistant epilepsy, to considerably improve health outcomes across India.

Similarly, in August 2024, Avesthagen Ltd and Apollo AyurVAID formed a strategic partnership to manufacture and market medical foods and dietary supplements. Following the collaboration, Avesthagen Ltd and Apollo AyurVAID will combine their skills and knowledge to design, manufacture, and market precision medical foods based on new tactics that improve patient care and promote holistic well-being.

Geographical Analysis

North America is expected to hold a significant position in the food as a medicine market share

North America holds a substantial position in the food as medicine market and is expected to hold most of the market share. This is due to the growing demand for foods and diet over medicine in the region with the increasing awareness among individuals. The increasing number of chronic diseases in the region is raising the demand for food-based therapies. There is a rising approach to food as a medicine that can be personalized.

The government bodies in the region are hosting summits and taking initiatives to increase awareness among individuals on food as medicine approaches. For instance, on January 31, 2024, the U.S. Department of Health and Human Services (HHS) hosted its first-ever Food is Medicine Summit in Washington, D.C., an all-day summit for stakeholders at the intersection between food and health. Secretary Xavier Becerra opened the summit by announcing three new public-private partnerships with Instacart, the Rockefeller Foundation, and Feeding America. All three partnerships will support HHS's nutrition goals.

Additionally, market players in the region are introducing advanced products of food as medicine and they are introducing new platforms to make the products available for all the individuals seeking these food-based treatments. These market players are expanding their businesses by adopting various strategies such as partnerships with each other and launching new products to make them meet the rising demand.

For instance, on August 26, 2024, Good Measures and Point32Health partnered to offer personalized nutrition support to members of Harvard Pilgrim Health Care, one of Point32Health's two insurance subsidiaries. The initiative provides nutrition counseling, food tracking, and other services through the Good Measures app, targeting conditions such as diabetes, heart disease, and obesity.

Similarly, on 16 Jul 2024, Season Health partnered with Mealogic at launch to deliver nutritionally tailored, culturally diverse meals to their patients. Mealogic has consistently provided low-cost, high-quality meals that have driven program adoption and delivered measurable clinical results nationwide.

There is an increasing shift and trend towards self-care through nutrition-based foods in the region which is also expected to contribute to the region's food as a medicine market share. Thus, with various strategies by the market players, increasing initiatives by the government bodies and the increasing incidence of chronic diseases, the food as a medicine market is expected to grow and the region is expected to dominate the global food as a medicine market share.

Market Segmentation

By Product Type

Dietary Supplements
Functional Foods and Beverages
Medical Foods
Whole Foods and Natural Foods

By Form

Capsules
Tablets
Powders
Liquid
Bars

By Application

Cardiovascular
Anti-Aging
Detoxification
Nutritional Deficiency
Diabetes
Anti-Cancer
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores
Supermarkets

By Region

North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
South America
- Brazil
- Argentina
- Rest of South America
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Middle East and Africa

Competitive Landscape

The major global players in the food as a medicine market include Bionova, Nestle, Primus Pharmaceuticals, Inc., Season Health, Mead Johnson & Company, LLC., SFI Health, Metagenics, Meiji Holdings Co., Ltd., Bitewell and Mealogic among others.

Key Developments

In April 2024, Vevolution, an Agrifoodtech investment platform, announced that it will organize a virtual pitch event themed "Food as Medicine". The sector is quickly gaining investment interest and encompasses areas like personalized nutrition, functional ingredients, sugar and salt alternatives, and microbiome health.
In March 2023, Instacart Health introduced tools for scaling 'Food as Medicine' programs. Healthcare professionals can now use Instacart's suite of digital technologies to improve collaborative care, promote healthy choices, and provide nutritious food to patients and their families, especially those who live in food deserts or require a medically restricted diet.

Why Purchase the Report?

To visualize the global food as a medicine market segmentation based on product type, form, application, distribution channel, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of food as a medicine market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global food as a medicine market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Form
3.3. Snippet by Application
3.4. Snippet by Distribution Channel
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising prevalence of chronic diseases
- 4.1.2. Restraints
  - 4.1.2.1. Limited awareness among individuals about food as a medicine
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Dietary Supplements*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Functional Foods and Beverages
6.4. Medical Foods
6.5. Whole Foods and Natural Foods

7. By Form

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
- 7.1.2. Market Attractiveness Index, By Form
7.2. Capsules*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Tablets
7.4. Powders
7.5. Liquid
7.6. Bars

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Cardiovascular*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Anti-Aging
8.4. Detoxification
8.5. Nutritional Deficiency
8.6. Diabetes
8.7. Anti-Cancer
8.8. Others

9. By Distribution Channel

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
9.5. Drug Stores
9.6. Supermarkets

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
  - 10.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 10.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  - 10.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  - 10.2.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.3.1. The U.S.
  - 10.2.3.2. Canada
  - 10.2.3.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
  - 10.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 10.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  - 10.3.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.4.1. Germany
  - 10.3.4.2. UK
  - 10.3.4.3. France
  - 10.3.4.4. Italy
  - 10.3.4.5. Spain
  - 10.3.4.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
  - 10.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 10.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  - 10.4.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.4.1. Brazil
  - 10.4.4.2. Argentina
  - 10.4.4.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
  - 10.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 10.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  - 10.5.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.4.1. China
  - 10.5.4.2. India
  - 10.5.4.3. Japan
  - 10.5.4.4. South Korea
  - 10.5.4.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
  - 10.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 10.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  - 10.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Bionova*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Nestle
12.3. Primus Pharmaceuticals, Inc.
12.4. Season Health
12.5. Mead Johnson & Company, LLC.
12.6. SFI Health
12.7. Metagenics
12.8. Meiji Holdings Co., Ltd.
12.9. Bitewell
12.10. Mealogic

LIST NOT EXHAUSTIVE